2-(3-溴苄基)异吲哚-1,3-二酮 | 183735-18-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 异吲哚及其衍生物
• 中文名称: 2-(3-溴苄基)异吲哚-1,3-二酮
• 英文名称: 2-(3-bromobenzyl)isoindoline-1,3-dione
• 英文别名: 2-[(3-bromophenyl)methyl]isoindole-1,3-dione
• CAS: 183735-18-4
• 化学式: C₁₅H₁₀BrNO₂
• mdl: MFCD05598731
• 分子量: 316.154
• InChiKey: HZNJTQRBGXEHBN-UHFFFAOYSA-N

物化性质

• 熔点：
  138-139 °C
• 沸点：
  445.7±28.0 °C(Predicted)
• 密度：
  1.604±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  19
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.066
• 拓扑面积：
  37.4
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2-(3-溴苄基)异吲哚-1,3-二酮 在 一水合肼 、 三乙胺 作用下， 以 甲醇 、 二氯甲烷 为溶剂， 反应 1.0h， 生成 3-溴苄基氨基甲酸叔丁酯
  参考文献：
  名称：

  Design and synthesis of novel and highly-active pan-histone deacetylase (pan-HDAC) inhibitors

  摘要：

  Histone deacetylase (HDAC) inhibitions are known to elicit anticancer effects. We designed and synthesized several HDAC inhibitors. Among these compounds, compound 40 exhibited a more than 10-fold stronger inhibitory activity compared with that of suberoylanilide hydroxamic acid (SAHA) against each human HDAC isozyme in vitro (IC50 values of 40: HDAC1, 0.0038μM; HDAC2, 0.0082μM; HDAC3, 0.015μM; HDAC8, 0.0060μM; HDAC4, 0.058μM; HDAC9, 0.0052μM; HDAC6, 0.058μM). The dose of the administered HDAC inhibitors that contain hydroxamic acid as the zinc-binding group may be reduced by 40. Because the carbostyril subunit is a time-tested structural component of drugs and biologically active compounds, 40 most likely exhibits good absorption, distribution, metabolism, excretion, and toxicity (ADMET). Thus, compound 40 is expected to be a promising therapeutic agent or chemical tool for the investigation of life process.

  DOI：

  10.1016/j.bmc.2014.05.001
• 作为产物：
  描述：

  3-溴苄溴 、 potassium phtalimide 以 N,N-二甲基甲酰胺 为溶剂， 反应 12.0h， 生成 2-(3-溴苄基)异吲哚-1,3-二酮
  参考文献：
  名称：

  COUMARIN-LIKE CYCLIC COMPOUND AS MEK INHIBITOR AND USE THEREOF

  摘要：

  公开号：

  EP3643308B1

文献信息

• [EN] SUBSTITUTED PYRIDINE DERIVATIVES AS FABI INHIBITORS<br/>[FR] DÉRIVÉS DE PYRIDINE SUBSTITUÉS EN TANT QU'INHIBITEURS DE FABI
  申请人：AURIGENE DISCOVERY TECH LTD

  公开号：WO2013080222A1

  公开（公告）日：2013-06-06

  The present invention provides substituted pyridine derivatives of formula (I), which may be therapeutically useful as as anti-bacterial agents, more particulalrly FabI inhibitors. Formula(I) in which R1 to R5 and L have the meanings given in the specification, and pharmaceutically acceptable salts thereof that are useful in the treatment and prevention in diseases or disorder, in particular their use in diseases or disorder where there is an advantage anti-bacterial agents, more particularly FabI inhibitors. The present invention also provides methods for synthesizing and administering the FabI inhibitor compounds. The present invention also provides pharmaceutical formulations comprising at least one of the FabI inhibitor compounds together with a pharmaceutically acceptable carrier, diluent or excipient therefor.

  本发明提供了式(I)的取代吡啶衍生物，其可能作为抗细菌剂，特别是FabI抑制剂，具有治疗用途。式(I)中，R1至R5和L具有说明书中给出的含义，以及用于治疗和预防疾病或失调的药用可接受盐，特别是在有优势使用抗细菌剂，尤其是FabI抑制剂的疾病或失调中的用途。本发明还提供了合成和管理FabI抑制剂化合物的方法。本发明还提供了包含至少一种FabI抑制剂化合物和用于其的药用可接受载体、稀释剂或助剂的药物制剂。
• Chemiluminescent energy transfer conjugates and their uses as labels in
  申请人：Bayer Corporation

  公开号：US06165800A1

  公开（公告）日：2000-12-26

  A new class of chemiluminescent acridinium or benzacridinium compounds is disclosed by virtue of forming an intramolecular energy transfer conjugate (ETC) between the acridinium or benzacridinium compound and a luminophore. A method of extending the emission wavelengths of acridinium or benzacridinium esters in order to further reduce or eliminate the emission spectral overlap between the parent polysubstituted aryl Acridinium Esters (DMAE) and Benzacridinium Esters (LEAE) is disclosed. The ETC's retain the unique desired properties of acridinium or benzacridinium compounds including complete light emission in very short period of time, monophasic emission spectrum, simplicity of triggering mechanism, ability of labeling the biological molecules of interest to form a tracer, and good stability. Additionally, the range of the emission spectrum of an acridinium or benzacridinium compound can now be shifted at will and at longer leap through the choice of a luminophore as the integral part of an ETC molecule. Disclosed are chemiluminescent labeled conjugates comprising an acridinium or benzacridinium moiety covalently attached to a luminophore via a spacer, said moiety further conjugated to a biological molecule of interest, wherein said spacer is of an appropriate length to allow the excited species generated from said moiety to transfer energy efficiently to said luminophore, resulting in the emission of light in the spectral region of said luminophore. Also disclosed are binding assays using said conjugates, test kits comprising said conjugates and methods of preparing the conjugates.

  一种新型的化学发光吖啶或苯基吖啶化合物类别通过形成吖啶或苯基吖啶化合物与发光团之间的分子内能量转移共轭（ETC）而被揭示。一种延长吖啶或苯基吖啶酯的发射波长的方法，以进一步减少或消除母体多取代芳基吖啶酯（DMAE）和苯基吖啶酯（LEAE）之间的发射光谱重叠也被揭示。ETC保留了吖啶或苯基吖啶化合物的独特期望性质，包括在非常短的时间内完全发光、单相发射光谱、触发机制的简单性、标记感兴趣的生物分子以形成示踪剂的能力以及良好的稳定性。此外，吖啶或苯基吖啶化合物的发射光谱范围现在可以通过选择作为ETC分子的组成部分的发光团来随意移动并延长跃迁。揭示了包括通过间隔连接共价连接到发光团的吖啶或苯基吖啶基团的化学发光标记共轭物，所述基团进一步与感兴趣的生物分子共轭，其中所述间隔具有适当长度，以允许从所述基团产生的激发态有效地将能量转移给所述发光团，导致在所述发光团的光谱区域发射光。还揭示了使用所述共轭物的结合测定、包含所述共轭物的检测试剂盒以及制备所述共轭物的方法。
• Discovery of dually acting small-molecule inhibitors of cancer-resistance relevant receptor tyrosine kinases EGFR and IGF-1R
  作者：Cornelius Hempel、Abdulkarim Najjar、Frank Totzke、Christoph Schächtele、Wolfgang Sippl、Christoph Ritter、Andreas Hilgeroth

  DOI：10.1039/c6md00329j

  日期：——

  and pyrrolo[2,3-b]pyridines with a 4-benzylamine substitution have been evaluated as inhibitors of the epidermal growth factor receptor (EGFR). Substituent effects on the determined protein kinase affinity have been discussed based on varied benzylamine residues at the differently substituted molecular scaffolds. Docking studies were carried out in order to explore the potential binding modes of the

  具有4-苄基胺取代的新型苯并芳基呋喃和吡咯并[2,3- b ]吡啶已被评估为表皮生长因子受体（EGFR）的抑制剂。基于在不同取代的分子支架上的不同苄胺残基，已经讨论了对确定的蛋白激酶亲和力的取代基作用。为了研究新型抑制剂的潜在结合方式，进行了对接研究。观察到的活性数据促进了对胰岛素样生长因子受体（IGF-1R）抑制作用的测量，已知它在通过EGFR抑制剂抵抗癌症的发展中起着重要作用IGF-1R受体异二聚化。我们确定了两种激酶的新型双重抑制剂，并报告了它们的第一个癌细胞生长抑制数据。
• “On water” nano-Cu₂O-catalyzed CO-free one-pot multicomponent cascade cyanation–annulation–aminolysis reaction toward phthalimides
  作者：Xiaowei Wen、Xiaojuan Liu、Zhiqi Yang、Menglan Xie、Yuxi Liu、Lipeng Long、Zhengwang Chen

  DOI：10.1039/d1ob00073j

  日期：——

  An efficient nano-Cu2O-catalyzed cascade multicomponent reaction of 2-halobenzoic acids and trimethylsilyl cyanide with diverse amines was developed using water as a solvent, affording versatile N-substituted phthalimide derivatives in moderate to excellent yields. This novel strategy features carbon monoxide gas-free, environmentally benign, one-pot multistep transformation, commercially available

  以水为溶剂，开发了2-卤代苯甲酸和三甲基甲硅烷基氰化物与多种胺的高效纳米Cu 2 O催化级联多组分反应，以中等至优异的收率提供了多种N-取代邻苯二甲酰亚胺衍生物。这种新颖的策略具有无一氧化碳气体，对环境无害，一锅多步转化，市售试剂，便宜的无任何添加剂的催化剂，宽泛的官能团耐受性和操作便利性的特点。
• Substituted pyridine derivatives as FabI inhibitors
  申请人：Aurigene Discovery Technologies Limited

  公开号：US09062002B2

  公开（公告）日：2015-06-23

  The present invention provides substituted pyridine derivatives of formula (I), which may be therapeutically useful as as anti-bacterial agents, more particularly FabI inhibitors. Formula (I) in which R1 to R5 and L have the meanings given in the specification, and pharmaceutically acceptable salts thereof that are useful in the treatment and prevention in diseases or disorder, in particular their use in diseases or disorder where there is an advantage anti-bacterial agents, more particularly FabI inhibitors. The present invention also provides methods for synthesizing and administering the FabI inhibitor compounds. The present invention also provides pharmaceutical formulations comprising at least one of the FabI inhibitor compounds together with a pharmaceutically acceptable carrier, diluent or excipient therefor.

  本发明提供了式（I）的取代吡啶衍生物，其作为抗细菌剂可能具有治疗用途，更具体地作为FabI抑制剂。式（I）中R1至R5和L具有规范中所给出的含义，以及其药学上可接受的盐，在治疗和预防疾病或紊乱方面有用，特别是在存在抗细菌剂优势的疾病或紊乱中使用，更具体地作为FabI抑制剂。本发明还提供了合成和给予FabI抑制剂化合物的方法。本发明还提供了包括至少一种FabI抑制剂化合物和药学上可接受的载体、稀释剂或赋形剂的制药配方。